A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A

Hemophilia A Clinical Trial

Official title:

A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05987449
• Other study ID #: WP44714
• Secondary ID: 2023-503906-35-0
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: September 21, 2023
• Est. completion date: June 16, 2032

Study information

• Verified date: May 2024
• Source: Hoffmann-La Roche
• Contact: Reference Study ID Number: WP44714 https://forpatients.roche.com
• Phone: 888-662-6728 (U.S. Only)
• Email: global-roche-genentech-trials[@]gene.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Study WP44714 is a Phase I/II, open-label, non-randomized, global, multicenter, multiple-ascending dose (MAD) study in adult and adolescent male participants with severe or moderate hemophilia A with or without factor VIII (FVIII) inhibitors. The aim is to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of multiple ascending doses of NXT007.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: June 16, 2032
• Est. primary completion date: June 16, 2032
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 12 Years to 59 Years

Eligibility

Inclusion Criteria:

• Body weight =40 kilograms (kg) at screening
• Diagnosis of severe (Factor VIII [FVIII] coagulant activity <1 IU/dL) or moderate (FVIII coagulant activity =1 IU/dL and =5 IU/dL) congenital hemophilia A with or without inhibitors against FVIII
• Participants with FVIII inhibitors: participants using recombinant activated factor VII (rFVIIa) or willing to switch to rFVIIa as primary bypassing agent for the treatment of breakthrough bleeds, trauma, or procedures
• Historic local FVIII inhibitor test results being available during screening to confirm any previous inhibitor history and current status
• Participants who previously successfully completed immune tolerance induction (ITI) must have done so at least 5 years before screening and must have no evidence of inhibitor recurrence (permanent or temporary) since. FVIII tolerance defined as <0.6 Bethesda unit (BU)/mL (<1.0 BU/mL only for laboratories with an historical sensitivity cutoff for inhibitor detection of 1.0 BU/mL) and in vivo recovery >66%
• Documentation of number and type of bleeding episodes in the last 24 weeks prior to enrollment
• Adequate hematologic function, defined as platelet count =100,000 cells/µL and hemoglobin =11 g/dL at the time of screening
• Adequate hepatic function defined as total bilirubin =1.5× age-adapted upper limit of normal (ULN) (excluding Gilbert syndrome) and both AST and ALT =3× age-adapted ULN at the time of screening, and no clinical signs or known laboratory/radiographic evidence consistent with cirrhosis
• Adequate renal function, defined as serum creatinine =2.5× age-adapted ULN and calculated creatinine clearance =30 mL/min by Cockroft-Gault formula
• Willingness and ability to comply with schedules visits, treatment plans, laboratory tests, and other study procedures

Exclusion Criteria:

• Inherited or acquired bleeding disorders other than congenital hemophilia A
• Ongoing or planned ITI therapy
• Previous or current treatment for thromboembolic disease (with the exception of previous catheter-associated thrombosis for which anti-thrombotic treatment is not currently ongoing) or signs of thromboembolic disease
• At high risk for thrombotic microangiopathy (TMA), including past personal or family history of TMA, in the investigator's judgment
• Personal history of ischemic heart disease, cerebrovascular disease, or diabetes mellitus
• Strong family history of ischemic heart disease or cerebrovascular disease (i.e., first degree relatives such as parents, full siblings, or children): male relatives diagnosed under the age of 55 years, females under the age of 65 years
• Other conditions (e.g., autoimmune conditions such as Systemic Lupus erythematosus and other systemic inflammatory disorders) that may currently increase the risk of bleeding or thrombosis
• History of clinically significant allergies
• Previous or concomitant malignancies or leukemia
• Receipt of any of the following:

i) An investigational drug to treat or reduce the risk of hemophilic bleeds within 5 half-lives of last drug administration or normalization of targeted parameters (e.g., anti-thrombin), whichever is longer; ii) A non-hemophilia-related investigational drug within last 30 days or 5 half-lives, whichever is shorter; iii) Any other investigational drug currently being administered or planned to be administered; iv) Prior gene therapy or gene therapy planned to be administered.

• Protein C activity, protein S free antigen, or anti-thrombin III activity levels below the lower limit of the reference range at screening
• Known HIV infection with CD4 counts <200 cells/µL
• History of severe allergic or anaphylactic reactions to monoclonal antibody therapy and to chimeric or humanized antibodies or fusion proteins
• Known hypersensitivity to Chinese hamster ovary cell products or to excipient content
• History or presence of an abnormal ECG that is deemed clinically significant, (e.g., complete left bundle branch block, second- or third -degree atrioventricular heart block), including atrial fibrillation or evidence of prior myocardial infarction
• QT interval corrected through use of Fridericia's formula (QTcF) >450 ms demonstrated by at least two ECGs >30 minutes apart
• History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias such as structural heart disease (e.g., severe left ventricular systolic dysfunction, left ventricular hypertrophy), coronary heart disease (symptomatic or with ischemia demonstrated by diagnostic testing), clinically significant electrolyte abnormalities (e.g., hypokalemia, hypomagnesemia, hypocalcemia), or family history of sudden unexplained death or long QT syndrome
• Current treatment with medications that are well known to prolong the QT interval

Related Conditions & MeSH terms

• Hemophilia A

Intervention

Drug:
• NXT007
Participants will receive NXT007 administered subcutaneously (SC), 2 loading doses once every two weeks (Q2W) followed by once every 4 weeks (Q4W) maintenance doses based on the schedule.

Locations

Country	Name	City	State
Canada	Hamilton Health Sciences Corporation	Hamilton	Ontario
Italy	Istituto Clinico Humanitas; Centro Trombosi e Malattie Emorragiche	Rozzano (MI)	Lombardia
New Zealand	Auckland Cancer Trial Centre; Ward 64, Auckland City Hospital,	Auckland
Poland	Uniwersyteckie Centrum Kliniczne; Klinika Hematologii i Transplantologii	Gda?sk
Poland	Instytut Hematologii i Transfuzjologii; Klinika Zaburze? Hemostazy i Chorób Wewn?trznych	Warsaw
Spain	Hospital Universitario la Paz; Servicio de Hematologia	Madrid
Spain	Hospital Regional Universitario Carlos Haya; Servicio de Hematologia	Malaga
United States	Indiana Hemophilia & Thrombosis center	Indianapolis	Indiana

Sponsors (1)

Lead Sponsor	Collaborator
Hoffmann-La Roche

Countries where clinical trial is conducted

United States,  Canada,  Italy,  New Zealand,  Poland,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence and Severity of Adverse Events, with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events Grading Scale		From Baseline until study completion or discontinuation (up to 7.5 years)
Primary	Number of Participants with at Least One Clinical Laboratory Test Abnormality for Hematology Parameters		From Baseline until study completion or discontinuation (up to 7.5 years)
Primary	Number of Participants with at Least One Clinical Laboratory Test Abnormality for Blood Chemistry Parameters		From Baseline until study completion or discontinuation (up to 7.5 years)
Primary	Number of Participants with at Least One Vital Sign Abnormality	The vital signs that will be assessed are body temperature, pulse rate, respiratory rate, and systolic and diastolic blood pressure.	From Baseline until study completion or discontinuation (up to 7.5 years)
Primary	Number of Participants with at Least One Abnormality on Electrocardiogram (ECG) Recordings	The ECG parameters that will be assessed are heart rate, PR interval, QRS interval, QT interval, and QTcF inteval.	From Baseline until study completion or discontinuation (up to 7.5 years)
Secondary	Plasma Concentration of NXT007 at Specified Timepoints		At prespecified timepoints from Day 1 to Day 155, and every 28 days from Day 169 until study completion (up to 7.5 years)
Secondary	Maximum Observed Plasma Concentration (Cmax) of NXT007 After the First Dose		At prespecified timepoints from Day 1 to Day 15
Secondary	Time to Maximum Observed Plasma Concentration (tmax) of NXT007 After the First Dose		At prespecified timepoints from Day 1 to Day 15
Secondary	Area Under the Plasma Concentration-Time Curve (AUC) of NXT007 After the First Dose		At prespecified timepoints from Day 1 to Day 15
Secondary	Number of Participants Testing Positive for Anti-Drug Antibodies Against NXT007 at Baseline and During Treatment with Study Drug		Baseline (predose on Day 1) and from first dose of study drug until study completion or discontinuation (up to 7.5 years)
Secondary	Number of Participants Testing Positive for Anti-Factor VIII Inhibitors at Baseline and During Treatment with Study Drug		Baseline (predose on Day 1) and from first dose of study drug until study completion or discontinuation (up to 7.5 years)
Secondary	Model-Based Annualized Bleeding Rate for Treated Bleeds		From first dose of study drug until study completion or discontinuation (up to 7.5 years)
Secondary	Mean Calculated Annualized Bleeding Rate for Treated Bleeds		From first dose of study drug until study completion or discontinuation (up to 7.5 years)
Secondary	Median Calculated Annualized Bleeding Rate for Treated Bleeds		From first dose of study drug until study completion or discontinuation (up to 7.5 years)
Secondary	Model-Based Annualized Bleeding Rate for All Bleeds		From first dose of study drug until study completion or discontinuation (up to 7.5 years)
Secondary	Mean Calculated Annualized Bleeding Rate for All Bleeds		From first dose of study drug until study completion or discontinuation (up to 7.5 years)
Secondary	Median Calculated Annualized Bleeding Rate for All Bleeds		From first dose of study drug until study completion or discontinuation (up to 7.5 years)
Secondary	Model-Based Annualized Bleeding Rate for Treated Spontaneous Bleeds		From first dose of study drug until study completion or discontinuation (up to 7.5 years)
Secondary	Mean Calculated Annualized Bleeding Rate for Treated Spontaneous Bleeds		From first dose of study drug until study completion or discontinuation (up to 7.5 years)
Secondary	Median Calculated Annualized Bleeding Rate for Treated Spontaneous Bleeds		From first dose of study drug until study completion or discontinuation (up to 7.5 years)
Secondary	Model-Based Annualized Bleeding Rate for Treated Joint Bleeds		From first dose of study drug until study completion or discontinuation (up to 7.5 years)
Secondary	Mean Calculated Annualized Bleeding Rate for Treated Joint Bleeds		From first dose of study drug until study completion or discontinuation (up to 7.5 years)
Secondary	Median Calculated Annualized Bleeding Rate for Treated Joint Bleeds		From first dose of study drug until study completion or discontinuation (up to 7.5 years)